Search

Search Constraints

You searched for: Author/Creator Rothenberg, Marc

Search Results

2. S420 The Histological Scoring System and Endoscopic Reference Score Are Complementary Assessments for Characterizing Fibrostenotic or Inflammatory Phenotypes in Patients with Eosinophilic Esophagitis. (October 2021)

3. S381 Esophageal Eosinophil Count Does Not Correlate With the Endoscopic Reference Score Remodeling Subscore in Placebo-Treated Eosinophilic Esophagitis Patients in the Phase 2 Proof-of-Concept and Phase 3 TREET Studies. (October 2021)

4. S1431 Similar Efficacy of Lirentelimab in Patients With New vs Prior Diagnoses of Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial. (October 2021)

5. S1421 Safety and Efficacy of Long-Term Treatment With Lirentelimab, A Monoclonal Antibody Against Siglec-8, in Patients With Eosinophilic Gastritis and/or Duodenitis. (October 2021)

6. S1405 Endoscopy and Systematic Biopsy of Patients With Moderate-Severe Unexplained Gastrointestinal Symptoms Compared With Healthy Controls: High Discovery Rate of Eosinophilic Gastritis and/or Eosinophilic Duodenitis. (October 2021)

7. 619 HIGH DISCOVERY RATE OF GASTRODUODENAL EOSINOPHILIA BUT NOT EOSINOPHILIC ESOPHAGITIS IN PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS. (17th September 2021)

8. 621 PL02.05 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8. (17th September 2021)

9. MicroRNA-21 Coordinates Human Multipotent Cardiovascular Progenitors Therapeutic Potential. (14th October 2014)

10. S387 Dupilumab Improves Clinical, Symptomatic, Histologic, and Endoscopic Aspects of EoE up to 24 Weeks: Pooled Results From Parts A and B of Phase 3 LIBERTY-EoE-TREET. (October 2022)